Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders
Adam K Bevan, Sandra Duque, Kevin D Foust, Pablo R Morales, Lyndsey Braun, Leah Schmelzer, Curtis M Chan, Mary McCrate, Louis G Chicoine, Brian D Coley, Paul N Porensky, Stephen J Kolb, Jerry R Mendell, Arthur H M Burghes, Brian K Kaspar, Adam K Bevan, Sandra Duque, Kevin D Foust, Pablo R Morales, Lyndsey Braun, Leah Schmelzer, Curtis M Chan, Mary McCrate, Louis G Chicoine, Brian D Coley, Paul N Porensky, Stephen J Kolb, Jerry R Mendell, Arthur H M Burghes, Brian K Kaspar
Abstract
Adeno-associated virus type 9 (AAV9) is a powerful tool for delivering genes throughout the central nervous system (CNS) following intravenous injection. Preclinical results in pediatric models of spinal muscular atrophy (SMA) and lysosomal storage disorders provide a compelling case for advancing AAV9 to the clinic. An important translational step is to demonstrate efficient CNS targeting in large animals at various ages. In the present study, we tested systemically injected AAV9 in cynomolgus macaques, administered at birth through 3 years of age for targeting CNS and peripheral tissues. We show that AAV9 was efficient at crossing the blood-brain barrier (BBB) at all time points investigated. Transgene expression was detected primarily in glial cells throughout the brain, dorsal root ganglia neurons and motor neurons within the spinal cord, providing confidence for translation to SMA patients. Systemic injection also efficiently targeted skeletal muscle and peripheral organs. To specifically target the CNS, we explored AAV9 delivery to cerebrospinal fluid (CSF). CSF injection efficiently targeted motor neurons, and restricted gene expression to the CNS, providing an alternate delivery route and potentially lower manufacturing requirements for older, larger patients. Our findings support the use of AAV9 for gene transfer to the CNS for disorders in pediatric populations.
Figures
References
- Kolb SJ., and, Kissel JT.2011Spinal muscular atrophy: A timely review Arch Neurolepub ahead of print).
- Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard al. (2011Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice Hum Mol Genet 20681–693.
- Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet al. (2010Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN Nat Biotechnol 28271–274.
- Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw al. (2010Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy Sci Transl Med 235ra42
- Anderton RS, Meloni BP, Mastaglia FL, Greene WK., and, Boulos S. Survival of motor neuron protein over-expression prevents calpain-mediated cleavage and activation of procaspase-3 in differentiated human SH-SY5Y cells. Neuroscience. 2011;181:226–233.
- La Bella V, Kallenbach S., and, Pettmann B. Expression and subcellular localization of two isoforms of the survival motor neuron protein in different cell types. J Neurosci Res. 2000;62:346–356.
- Vitte JM, Davoult B, Roblot N, Mayer M, Joshi V, Courageot al. (2004Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload Am J Pathol 1651731–1741.
- Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim al. (2008SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing Cell 133585–600.
- Burghes AH., and, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick. Nat Rev Neurosci. 2009;10:597–609.
- Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar al. (2009Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons Mol Ther 171187–1196.
- Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM., and, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59–65.
- Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR., and, Samulski RJ. Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates. Mol Ther. 2011;19:1058–1069.
- Wang DB, Dayton RD, Henning PP, Cain CD, Zhao LR, Schrott al. (2010Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed Mol Ther 182064–2074.
- Alvarez-Saavedra M, Carrasco L, Sura-Trueba S, Demarchi Aiello V, Walz K, Neto al. (2010Elevated expression of MeCP2 in cardiac and skeletal tissues is detrimental for normal development Hum Mol Genet 192177–2190.
- Forsayeth JR., and, Bankiewicz KS. AAV9: Over the Fence and Into the Woods. Mol Ther. 2011;19:1006–1007.
- Daniel C, Rojo MG, Klossa J, Mea VD, Booker D, Beckwith al. (2011Standardizing the use of whole slide images in digital pathology Comput Med Imaging Graph
- Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac al. (2009Follistatin gene delivery enhances muscle growth and strength in nonhuman primates Sci Transl Med 16ra15
- Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao al. (2008Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat Hum Gene Ther 191359–1368.
- Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng al. (2010Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs Mol Ther 181501–1508.
- Pacak CA, Sakai Y, Thattaliyath BD, Mah CS., and, Byrne BJ. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 2008;6:13.
- Zincarelli C, Soltys S, Rengo G., and, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073–1080.
- Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay al. (2008A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs Mol Ther 161944–1952.
- Gavrilina TO, McGovern VL, Workman E, Crawford TO, Gogliotti RG, DiDonato al. (2008Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect Hum Mol Genet 171063–1075.
- Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek al. (2011Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy Sci Transl Med 372ra18
- Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan al. (2010CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy J Clin Invest 1201253–1264.
- Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna al. (2011Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer Mol Ther 191070–1078.
- Zerres K, Rudnik-Schöneborn S, Forrest E, Lusakowska A, Borkowska J., and, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146:67–72.
- Park GH, Kariya S., and, Monani UR. Spinal muscular atrophy: new and emerging insights from model mice. Curr Neurol Neurosci Rep. 2010;10:108–117.
- Fu H, Dirosario J, Killedar S, Zaraspe K., and, McCarty DM. Correction of Neurological Disease of Mucopolysaccharidosis IIIB in Adult Mice by rAAV9 Trans-Blood-Brain Barrier Gene Delivery. Mol Ther. 2011;19:1025–1033.
- Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer al. (2009Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy Proc Natl Acad Sci USA 10616363–16368.
- Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor al. (2007Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial Lancet 3692097–2105.
- Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus al. (2010Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors Hum Gene Ther 21704–712.
- Calcedo R, Vandenberghe LH, Gao G, Lin J., and, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–390.
- van der Marel S, Comijn EM, Verspaget HW, van Deventer S, van den Brink GR, Petry al. (2011Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: Implications for gene therapy Inflamm Bowel Disepub ahead of print).
- Chen CL, Jensen RL, Schnepp BC, Connell MJ, Shell R, Sferra al. (2005Molecular characterization of adeno-associated viruses infecting children J Virol 7914781–14792.
- Erles K, Sebökovà P., and, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV) J Med Virol. 1999;59:406–411.
- Tydén G, Kumlien G., and, Efvergren M. Present techniques for antibody removal. Transplantation. 2007;84 12 Suppl:S27–S29.
- Caley DW., and, Maxwell DS. Development of the blood vessels and extracellular spaces during postnatal maturation of rat cerebral cortex. J Comp Neurol. 1970;138:31–47.
- Amor S, Puentes F, Baker D., and, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129:154–169.
- Ballas N, Lioy DT, Grunseich C., and, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci. 2009;12:311–317.
- Ilieva H, Polymenidou M., and, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187:761–772.
- Xie J, Xie Q, Zhang H, Ameres SL, Hung JH, Su al. (2011MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression Mol Ther 19526–535.
- Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown al. (2010Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB) Mol Ther 18570–578.
- Jang JH, Schaffer DV., and, Shea LD.2011Engineering biomaterial systems to enhance viral vector gene delivery Mol Therepub ahead of print).
- Hester, ME, Murtha, MJ, Song, S, Rao, M, Miranda, CJ, Meyer, al. Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes Mol Therepub ahead of print).
- Bevan AK, Hutchinson KR, Foust KD, Braun L, McGovern VL, Schmelzer al. (2010Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery Hum Mol Genet 193895–3905.
- Heier CR, Satta R, Lutz C., and, DiDonato CJ. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet. 2010;19:3906–3918.
- Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA., and, Lorson CL. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet. 2010;19:4059–4071.
- Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system Mol Therepub ahead of print).
- Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou al. (2004Clades of Adeno-associated viruses are widely disseminated in human tissues J Virol 786381–6388.
Source: PubMed